Hao Fu
Impact in
- Cancer Research top 5%
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Advanced biosensing and bioanalysis techniques 8
- Oncology 44
- Cancer-related Molecular Pathways 11
- Peptidase Inhibition and Analysis 11
- Co-authors
- Yaping Du (15 shared papers)Yourong Duan (17 shared papers)Yong Jiang (7 shared papers)Zhong Liang (6 shared papers)Haojun Chen (16 shared papers)Chuanrong Chen (10 shared papers)Jianlin Shi (5 shared papers)Chunlei Zhu (10 shared papers)
- Journals
- BMC Cancer (4 papers)ACS Nano (4 papers)Advanced Science (4 papers)Biomaterials (4 papers)Clinical Cancer Research (3 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Hao Fu
151 papers receiving 3.2k citations
Hao Fu's Hit Papers
Peers
Comparison fields: 5 of 139
- Cancer Research 437
- Biomaterials 375
- Oncology 738
- Biomedical Engineering 794
- Molecular Biology 1.0k
Countries citing papers authored by Hao Fu
This map shows the geographic impact of Hao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Fu more than expected).
Fields of papers citing papers by Hao Fu
This network shows the impact of papers produced by Hao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Fu. The network helps show where Hao Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Hao Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 201 | |
| 2 | 2020 | 123 | |
| 3 | 2023 | 112 | |
| 4 | 2023 | 97 | |
| 5 | Pt-Modified High Entropy Rare Earth Oxide for Efficient Hydrogen Evolution in pH-Universal Environments Hit paper breakdown → | 2024 | 90 |
| 6 | 2022 | 75 | |
| 7 | 2020 | 74 | |
| 8 | 2023 | 68 | |
| 9 | 2013 | 63 | |
| 10 | 2021 | 61 | |
| 11 | 2022 | 59 | |
| 12 | 2024 | 58 | |
| 13 | 2023 | 56 | |
| 14 | 2015 | 56 | |
| 15 | 2021 | 45 | |
| 16 | 2023 | 44 | |
| 17 | 2020 | 44 | |
| 18 | Superporous sponge prepared by secondary network compaction with enhanced permeability and mechanical properties for non-compressible hemostasis in pigs Hit paper breakdown → | 2024 | 44 |
| 19 | Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. | 1998 | 44 |
| 20 | 2012 | 43 |
About Hao Fu
Hao Fu is a scholar working on Molecular Biology, Oncology, Biomedical Engineering, Pulmonary and Respiratory Medicine and Cancer Research, having authored 164 papers that have together received 3.3k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (25 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer-related Molecular Pathways (11 papers), Peptidase Inhibition and Analysis (11 papers), Nanoparticle-Based Drug Delivery (10 papers), Advanced biosensing and bioanalysis techniques (8 papers) and Catalytic Processes in Materials Science (8 papers). The work is most often cited by research in Cancer Research (437 citations), Biomaterials (375 citations), Oncology (738 citations), Biomedical Engineering (794 citations) and Molecular Biology (1.0k citations). Hao Fu has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Yaping Du, Yourong Duan, Yong Jiang, Zhong Liang, Haojun Chen, Chuanrong Chen, Jianlin Shi, Chunlei Zhu, Linqi Shi and Minghui Xiao. Their work appears in journals such as BMC Cancer, ACS Nano, Advanced Science, Biomaterials and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.